single-arm

OTHER2 trials

Sponsors

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., University Medical Centre Johannes Gutenberg-University Mainz

Conditions

HealthyLow risk acute pulmonary embolism

Phase 4

Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE)

Active, not recruitingNL-OMON45455

University Medical Centre Johannes Gutenberg-University MainzLow risk acute pulmonary embolism

Start: 2017-07-03Target: 143Updated: 2024-02-28

Unknown Phase

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

CompletedNCT02205827

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Healthy

Start: 2014-04-30End: 2014-05-31Updated: 2020-05-20